(101 Health Steps) Editor’s comments: For those who at a very dangerous point to chronic disease, solutions are available. The article below by Dr. Tomas Lodi explains other solutions for individuals that are really pushing death. Other options are available.
A kindler, gentler cancer treatment
(Anoasisofhealing.com) In order for any cell to absorb sugar, insulin is required. Insulin is the key that opens the lock on the cell to allow sugar to pass through. The locks on the cell surface are called insulin receptors. Cancer cells have developed a very simple but effective strategy which allows them to get more of the available sugar than their neighbors, the non-cancerous cells. They simply have many more insulin receptors than non-cancerous cells! Having many more receptors, cancer cells are able to bind and use more of the available insulin than all the other cells. So whether one eats a banana or a candy bar, the cancer is fed first and the rest of the cells get the leftovers.
At an Oasis of Healing we use this knowledge to target the cancer cell with cytotoxic agents (chemotherapy). By administering small amounts of insulin, we are able to select the cancer cells from amongst all the other cells in the body because they bind the insulin much more quickly. There are a multitude of effects upon cells when insulin binds to them and one of these effects is that the cells become more permeable (creating openings). Once the cancer cells have been targeted by the insulin to open their doors, we administer small amounts of the appropriate chemotherapeutic drugs, from 5% to 10% of the standard dose. Much of what we administer becomes absorbed into the cancer cells (permeable) and not the normal cells (relatively hard). IPT is able, therefore, to take advantage of the powerful cytotoxic (cell-killing) effects of standard chemotherapy without having to use high doses.
Because the dosing is low, side effects are minimized
and the treatments can be given more frequently
giving cancer cells less time to become resistant to the drugs.
A useful metaphor:
A conventional oncologist finds out that there is a burglar in the kitchen, so he throws a hand grenade into the kitchen.
We find out that there is a burglar in the kitchen so we inject some poison into a mosquito and send it into the kitchen. We feel very strongly that it is important to keep the kitchen intact. We also want to know that even if the burglar escaped through an open window, having been bitten, he will not survive very long.
What Drugs or Protocols are used with IPT?
We maintain membership in the American Society of Clinical Oncology (ASCO), attend conferences, read journals and communicate with colleagues in order to maintain a current knowledge base regarding all new drugs and protocols being used in the conventional treatment of cancer. We do this so that IPT can continue to be as effective as possible by using the best of standard therapies in a rational manner.
We take very seriously our Hippocratic Oath.
“Primum non nocere” or “First, do no harm”.
If we significantly harm the immune system in our efforts to destroy the cancer, we will have done a great and perhaps fatal, disservice. For it is the immune system which keeps us clean, renewed and protected from infections, toxins and cancer.
And there is a answer for cancer; it is called a healthy immune system!
Cancer cells have also developed another strategy to survive that IPT uses to it’s advantage. Not only are there many more insulin receptors on cancer cells but there are also many more “growth hormone” receptors, called IGF-1 and IGF-2. The acronym IGF stands for Insulin-like Growth Factor and therefore insulin can also bind to the IGF receptors. When these receptors are stimulated, cells are triggered to begin the process of dividing. Since many chemotherapeutic drugs are designed to kill cells which are actively dividing, stimulating the cancer cells to divide just before giving the chemotherapy actually increases the number of cancer cells that will be killed during the IPT treatment.
So, it becomes clear that IPT kills cancer by using the same strategies that cancer uses to kill people.
IPT REFERENCES
1) Insulin Stimulates Cell Replication
a) Santisteban G. Biochem & Biophys Res Comm. 1985;132:1174
b) Cullen J. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res.. 1990;50:48-53.
c) Papa V. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1900;86:1503-1510
d) Holdaway I. Hormone binding by human mammary carcinoma. Cancer Res. 1977;37:1946-1952.
2) Insulin, Growth Hormone and IGFs
a) Spring-Mills E. Immunoreactive hormones in human breast tissues. Surgery. Dec 1983:946-950
b) Zapf J. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Hormone Res. 1986;24:121-130
c) Furlanetto R. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res. 1984;44:2122-2128.
d) Wichert T. Insulin-like growth factor-1 is an autocrine regular of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000:4573-4581.
e) Pavelic K. Insulin and glucagons secretion by renal adenocarcinoma. Cancer. 1981;48:98-100.
f) Pavelic K. Carcinomas of the cervix and corpus uteri in humans: stage-dependent blood levels of substance(s) immunologically cross-reactive with insulin. J Natl Cancer Inst. 1982;68:891-894.
g) Pavelic K. Correlation of substances immunolgoically cross-reactive with insulin, glucose and growth hormone in Hodgkin?��Ǩ�Ѣs lymphoma patients. Cancer Lett. 1982;17:81-86.
h) Cullin J. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990;50:48-53.
i) McCarty M. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-1 down-regulation. Med Hypoth. 2001;56:12-16
3) Insulin as Potentiator
a) Alabaster O. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Europ J Cancer Oncol. 1981;17:1223-1228.
b) Schilisky R. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharm. 1981;30:1537-1542.
c) Hug V. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tissue. Cancer Res. 1986;46:147-152.
d) Gross G. Perturbation by insulin of human breast cancer cell kinetics. Cancer Res. 1984;44:3570-3575.
4) Clinical Study
a) Lasalvia-Prisco E, Cucchi S, Vazquez J et al. Insulin-induced
enhancement of antitumoral response to methotrexate in breast cancer patients.
Cancer Chemother Pharmacol. 2004;53(3):220-4.
5) Insulin Therapy in Cancer
a) Neufeld O. Insulin therapy in terminal cancer: a preliminary report. J Am Geriatr Soc. 1962;10:274-276.
Related posts:
